Nuvectra (NASDAQ:NVTR) vs. Interpace Diagnostics Group (NASDAQ:IDXG) Critical Survey
Nuvectra (NASDAQ:NVTR) and Interpace Diagnostics Group (NASDAQ:IDXG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.
Institutional & Insider Ownership
72.6% of Nuvectra shares are owned by institutional investors. Comparatively, 23.7% of Interpace Diagnostics Group shares are owned by institutional investors. 2.9% of Nuvectra shares are owned by company insiders. Comparatively, 2.8% of Interpace Diagnostics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings for Nuvectra and Interpace Diagnostics Group, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Interpace Diagnostics Group||0||0||3||0||3.00|
Nuvectra presently has a consensus price target of $10.67, indicating a potential upside of 635.63%. Interpace Diagnostics Group has a consensus price target of $3.33, indicating a potential upside of 344.44%. Given Nuvectra’s higher probable upside, equities analysts plainly believe Nuvectra is more favorable than Interpace Diagnostics Group.
This table compares Nuvectra and Interpace Diagnostics Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Interpace Diagnostics Group||-65.86%||-42.91%||-28.66%|
Volatility & Risk
Nuvectra has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Interpace Diagnostics Group has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.
Valuation & Earnings
This table compares Nuvectra and Interpace Diagnostics Group’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nuvectra||$48.83 million||0.53||-$48.13 million||($3.19)||-0.45|
|Interpace Diagnostics Group||$21.90 million||1.31||-$12.19 million||($0.43)||-1.74|
Interpace Diagnostics Group has lower revenue, but higher earnings than Nuvectra. Interpace Diagnostics Group is trading at a lower price-to-earnings ratio than Nuvectra, indicating that it is currently the more affordable of the two stocks.
Interpace Diagnostics Group beats Nuvectra on 7 of the 12 factors compared between the two stocks.
Nuvectra Company Profile
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.